Wai Yuen Tong Medicine Holdings Limited has announced its final results for the year ended 31 March 2025. The company reported a revenue from continuing operations of HK$745.3 million, a decrease of 4.9% compared to HK$783.9 million in the previous year. The gross profit from continuing operations also saw a decline of 4.6%, amounting to HK$376.5 million, down from HK$394.8 million. The profit for the year showed a significant increase of 77.5%, reaching HK$7.1 million from HK$4.0 million in the prior year. Earnings per share rose by 148.5%, from a loss of 1.30 HK cents to a positive 0.63 HK cents. The net assets value as of 31 March 2025 was reported at HK$1,179.6 million, marking a decline of 14.9% from HK$1,385.5 million as of the previous year-end. Additionally, cash and cash equivalents decreased by 14.6% to HK$132.3 million. The gearing ratio improved, dropping from 21.7% to 17.9%. No outlook or guidance for future periods was provided in the announcement.